STOCK TITAN

Ocumetics Technology CP (OTCFF) Stock News

OTCFF OTC
Rhea-AI Summary

Ocumetics Technology (OTCFF) is preparing for Group Two first-in-human lens implantations in Mexico City, with patient recruitment underway. Manufacturing and testing of redesigned lenses are complete, delivery systems have reached the clinic, and enhanced protocols have been submitted to its ethics committee.

The study will assess safety and near- and distance-vision performance; Group One focused on safety. Final site initiation and surgeon training remain ahead of implantation. The company expects initial results by year-end 2026 and data for potential negotiations with ophthalmic companies very early in 2027, contingent on Group Two results meeting or exceeding objectives. Evaluation of Group One 12-month results has begun, with reporting expected shortly.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Ocumetics Technology (OTCFF) appointed Sandi Gilbert to its board and named President and CEO Dean Burns as chairman. Gilbert’s director appointment remains subject to TSX Venture Exchange approval.

Gilbert returns to the board with capital markets and venture investment experience. She founded DealPoint and serves as managing partner of InterGen Capital. Burns said the company will draw on her capital markets experience immediately as it continues to secure funding for its next stage of growth.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management

FAQ

What is the current stock price of Ocumetics Technology CP (OTCFF)?

Ocumetics Technology CP (OTCFF) last closed at $0.2662.

What is the market cap of Ocumetics Technology CP (OTCFF)?

The market cap of Ocumetics Technology CP (OTCFF) is approximately $35.8M.